REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • March 11th, 2010 • Oxigene Inc • Biological products, (no disgnostic substances) • New York
Contract Type FiledMarch 11th, 2010 Company Industry JurisdictionThis REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of March 10, 2010, is by and among OXiGENE, Inc., a Delaware corporation with offices located at 701 Gateway Blvd, Suite 210, South San Francisco, CA 94080 (the “Company”), and each of the undersigned buyers (each, a “Buyer,” and collectively, the “Buyers”).
VOTING AGREEMENTVoting Agreement • March 11th, 2010 • Oxigene Inc • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledMarch 11th, 2010 Company Industry JurisdictionVOTING AGREEMENT, dated as of March 10, 2010 (this “Agreement”), by and among OXiGENE, Inc., a Delaware corporation with offices located at 701 Gateway Blvd, Suite 210, South San Francisco, CA 94080 (the “Company”) and Symphony ViDA Holdings LLC, a Delaware limited liability company with offices located at 875 Third Avenue, 18th Floor, New York, NY 10022 (the “Stockholder”).
AMENDMENT NO. 3 TO STOCKHOLDER RIGHTS AGREEMENTStockholder Rights Agreement • March 11th, 2010 • Oxigene Inc • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledMarch 11th, 2010 Company Industry JurisdictionThis Amendment No. 3 to Stockholder Rights Agreement (the “Amendment”), dated as of March 10, 2010, by and between OXiGENE, Inc., a Delaware corporation (the “Company”), and American Stock Transfer & Trust Company, LLC (the “Rights Agent”), amends that certain Stockholder Rights Agreement, dated as of March 24, 2005, as amended as of October 1, 2008 and October 14, 2009, between the Company and the Rights Agent (as so amended, the “Agreement”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 11th, 2010 • Oxigene Inc • Biological products, (no disgnostic substances) • New York
Contract Type FiledMarch 11th, 2010 Company Industry JurisdictionThis SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of March 10, 2010, is by and among OXiGENE, Inc., a Delaware corporation with offices located at 701 Gateway Blvd, Suite 210, South San Francisco, CA 94080 (the “Company”), and the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the “Buyers”).